參考文獻 |
1. Zhou, X., et al., A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma. Nature Communications, 2021. 12(1): p. 5189.
2. Lisa Licitra, J.B., Esteban Cvitkovic, Cesare Grandi, and P.B. Silvia Spinazze, Gemma Gatta, Roberto Molinari, Cancer of the nasopharynx. Critical Reviews in Oncology/Hematology 2003.
3. Thorley-Lawson, D.A., et al., The pathogenesis of Epstein–Barr virus persistent infection. Current Opinion in Virology, 2013. 3(3): p. 227-232.
4. Li, X., et al., HLA associations with nasopharyngeal carcinoma. Curr Mol Med, 2009. 9(6): p. 751-65.
5. Timmy Richardo , P.P., Chawalit Ngernsombat ,, H.I. Nurulfitri Wisetyaningsih , Hironori Yoshiyama and, and T. Janvilisri, Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis. cancers, 2020.
6. Anne W.M. Lee, W.T.N.a., Y.H. Chan b, Henry Sze a, Connie Chan a, T.H. Lam The battle against nasopharyngeal cancer. Radiotherapy and Oncology 2012.
7. Nicola, N.A. and J.J. Babon, Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev, 2015. 26(5): p. 533-44.
8. Gearing, D.P., et al., Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. The EMBO Journal, 1991. 10(10): p. 2839-2848.
9. Stahl, N., et al., Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science, 1994. 263(5143): p. 92-5.
10. Efthymiou, A.G., et al., Self-renewal and cell lineage differentiation strategies in human embryonic stem cells and induced pluripotent stem cells. Expert Opin Biol Ther, 2014. 14(9): p. 1333-44.
11. Schaper, F., et al., Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J, 1998. 335 ( Pt 3): p. 557-65.
12. Schiemann, W.P., J.L. Bartoe, and N.M. Nathanson, Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase. Evidence for participation of multiple signaling pathways which converge at Ras. J Biol Chem, 1997. 272(26): p. 16631-6.
13. Martini, M., et al., PI3K/AKT signaling pathway and cancer: an updated review. Ann Med, 2014. 46(6): p. 372-83.
14. Hirai, H., P. Karian, and N. Kikyo, Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. Biochem J, 2011. 438(1): p. 11-23.
15. Liu, S.C., et al., Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest, 2013. 123(12): p. 5269-83.
16. Liu, S.C., et al., Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling. Nat Commun, 2018. 9(1): p. 5105.
17. Trouillas, M., et al., The LIF cytokine: towards adulthood. Eur Cytokine Netw, 2009. 20(2): p. 51-62.
18. Liu, S.C. and Y.S. Chang, Role of leukemia inhibitory factor in nasopharyngeal carcinogenesis. Mol Cell Oncol, 2014. 1(1): p. e29900.
19. Liu, H., et al., The Hippo pathway regulates stem cell proliferation, self-renewal, and differentiation. Protein Cell, 2012. 3(4): p. 291-304.
20. Duluc, D., et al., Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood, 2007. 110(13): p. 4319-30.
21. Flaumenhaft, R. and K. De Ceunynck, Targeting PAR1: Now What? Trends Pharmacol Sci, 2017. 38(8): p. 701-716.
22. Zhu, Q., et al., The activation of protease-activated receptor 1 mediates proliferation and invasion of nasopharyngeal carcinoma cells. Oncol Rep, 2012. 28(1): p. 255-61.
23. Koukos, G., et al., Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life, 2011. 63(6): p. 412-8.
24. Seeley, S., et al., Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol, 2003. 10(11): p. 1033-41.
25. Mosnier, L.O., et al., Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood, 2012. 120(26): p. 5237-46.
26. Sebastiano, M., et al., A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling. Blood, 2017. 129(7): p. 883-895.
27. Trivedi, V., et al., Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell, 2009. 137(2): p. 332-43.
28. Flynn, A.N. and A.G. Buret, Proteinase-activated receptor 1 (PAR-1) and cell apoptosis. Apoptosis, 2004. 9(6): p. 729-37.
29. Cheng, T., et al., Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med, 2003. 9(3): p. 338-42.
30. Mosnier, L.O. and J.H. Griffin, Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J, 2003. 373(Pt 1): p. 65-70.
31. Chin, A.C., et al., Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A, 2003. 100(19): p. 11104-9.
32. Fortunato, T.M., et al., Expression of protease-activated receptor 1 and 2 and anti-tubulogenic activity of protease-activated receptor 1 in human endothelial colony-forming cells. PLoS One, 2014. 9(10): p. e109375.
33. Yang, R., et al., Combined upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 predicts unfavorable prognosis in human nasopharyngeal carcinoma. Onco Targets Ther, 2013. 6: p. 1139-46.
34. Wojtukiewicz, M.Z., et al., Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. Cancer Metastasis Rev, 2015. 34(4): p. 775-96.
35. Erturk, K., et al., Clinical significance of serum protease activated receptor1 levels in patients with lung cancer. Eur Rev Med Pharmacol Sci, 2016. 20(2): p. 243-9.
36. Gurbel, P.A., Y.H. Jeong, and U.S. Tantry, Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opin Investig Drugs, 2011. 20(10): p. 1445-53.
37. Flaumenhaft, R., Protease-Activated Receptor-1 Signaling: The Big Picture. Arterioscler Thromb Vasc Biol, 2017. 37(10): p. 1809-1811.
38. Aisiku, O., et al., Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood, 2015. 125(12): p. 1976-85.
39. Zhang, C., et al., High-resolution crystal structure of human protease-activated receptor 1. Nature, 2012. 492(7429): p. 387-92.
40. Morrow, D.A., et al., Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med, 2012. 366(15): p. 1404-13.
41. Gryka, R.J., L.F. Buckley, and S.M. Anderson, Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Drugs R D, 2017. 17(1): p. 65-72.
42. Ungar, L., et al., Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. J Am Heart Assoc, 2018. 7(24): p. e009609.
43. Reggiani, F., et al., YAP and TAZ Are Not Identical Twins. Trends Biochem Sci, 2021. 46(2): p. 154-168.
44. Zanconato, F., M. Cordenonsi, and S. Piccolo, YAP/TAZ at the Roots of Cancer. Cancer Cell, 2016. 29(6): p. 783-803.
45. Piccolo, S., S. Dupont, and M. Cordenonsi, The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev, 2014. 94(4): p. 1287-312.
46. Shin, E. and J. Kim, The potential role of YAP in head and neck squamous cell carcinoma. Exp Mol Med, 2020. 52(8): p. 1264-1274.
47. Dupont, S., et al., Role of YAP/TAZ in mechanotransduction. Nature, 2011. 474(7350): p. 179-83.
48. Totaro, A., T. Panciera, and S. Piccolo, YAP/TAZ upstream signals and downstream responses. Nat Cell Biol, 2018. 20(8): p. 888-899.
49. Kapoor, A., et al., Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell, 2014. 158(1): p. 185-197.
50. Zanconato, F., et al., Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol, 2015. 17(9): p. 1218-27.
51. Johnson, R. and G. Halder, The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov, 2014. 13(1): p. 63-79.
52. Huang, Z., et al., YAP1 Promotes Tumor Invasion and Metastasis in Nasopharyngeal Carcinoma with Hepatitis B Virus Infection. Onco Targets Ther, 2020. 13: p. 5629-5642.
53. Zhou, Y., R. Yang, and G. Ma, [YAP1 knockdown suppresses the proliferation, migration and invasion of human nasopharyngeal carcinoma cells]. Nan Fang Yi Ke Da Xue Xue Bao, 2019. 39(3): p. 286-291.
54. Chen, Y.H., et al., Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts. J Biol Chem, 1994. 269(44): p. 27372-7.
55. Parrales, A., et al., ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation. Cell Signal, 2013. 25(4): p. 829-38.
56. Kawazoe, T., et al., Autocrine Leukemia Inhibitory Factor Promotes Esophageal Squamous Cell Carcinoma Progression via Src Family Kinase-Dependent Yes-Associated Protein Activation. Mol Cancer Res, 2020. 18(12): p. 1876-1888.
57. Li, X., et al., LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget, 2014. 5(3): p. 788-801.
58. Mo, J.S., et al., Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev, 2012. 26(19): p. 2138-43.
59. Guo, L. and L. Teng, YAP/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol, 2015. 46(4): p. 1444-52.
60. Fujimoto, D., et al., PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway. Oncotarget, 2015. 6(33): p. 34788-99.
61. Zanconato, F., et al., YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol, 2016. 29: p. 26-33. |